Piper Sandler Reiterates Its ‘Overweight’ Rating on AbbVie Inc. (ABBV) with a $231 PT

AbbVie Inc. (NYSE:ABBV) is one of the 15 Best Stocks to Invest in for Financial Stability.

Piper Sandler Reiterates Its ‘Overweight’ Rating on AbbVie Inc. (ABBV) with a $231 PT

On September 12, 2025, Piper Sandler reiterated its ‘Overweight’ rating on AbbVie Inc. (NYSE:ABBV) with a $231 price target. This comes after the company settled with abbreviated New Drug Application (ANDA) filers over Rinvoq.

The agreement delays generic entry until April 2037, which is four years beyond the expiration of key composition IP in 2033. Thus, it provides AbbVie Inc. (NYSE:ABBV) with an extended exclusivity window. The investment firm noted that the final years of exclusivity often result in peak sales with lower R&D and marketing costs. Looking ahead, analysts believe the settlement enhances the company’s long-term earnings outlook and justifies multiple expansion from its current value, as Rinvoq is projected to surpass $10 billion in annual U.S. sales by 2030.

AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company, develops and markets innovative medicines across immunology, oncology, neuroscience, eye care, virology, aesthetics, and other therapeutic areas. It is one of the Best Stocks To Buy.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.